LABORATORY BIOSAFETY IN THE UNITED STATES FOR CLIAC DELIBERATION

Burton W. Wilcke, Jr., PhD

CLIAC Chair

November 6, 2014

1. **Should clinical laboratories conduct periodic systematic reviews of their inventories of infectious agents?**
2. **If so, are there agents of special concern and how should laboratories manage inventory control?**
3. **How prepared are clinical laboratories in the US to handle novel pathogens like Ebola?**
4. **Do clinical laboratories need more training in laboratory safety?**

5. **Are there technologic advances that are or will be available in the near future to better assure the safety of personnel who perform diagnostic testing?**

6. **Who should assure that automated laboratory instruments can process human blood and body fluids safely and that the instruments do not create an infectious disease risk to their users? Options include manufacturers, an independent organization, a government agency, or others?**

7. **How can laboratories better assess and ensure adherence to safety standards? Is there a need for an enhanced role for laboratory inspectors to help assure that laboratories establish and observe safety procedures to ensure protection from hazards and biohazardous materials?**